ArticleNature medicine2021
Evolution of delayed resistance to immunotherapy in a melanoma responder.
Open access · greenAbstract read
In one paragraph
Article in Nature medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 81 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
81citing papers in PubMed, 2 pooled it
7.7field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
81 citing papers in PubMed, 2 syntheses or guidelines pooled it, 125 citations in OpenAlex.
- Survival after cessation of immunotherapies in melanoma: A systematic review and meta-analysis.Journal of the European Academy of Dermatology and Venereology : JEADV · 2025Pooled it
- Multilevel Mechanisms of Cancer Drug Resistance.International journal of molecular sciences · 2024Pooled it
- Efficacy, safety, and predictive biomarkers of neoadjuvant nab-paclitaxel and pembrolizumab in hormone receptor-positive breast cancer: A randomized pilot trial.Nature communications · 2025Trial
- Improved prognosis and evidence of enhanced immunogenicity in tumor and circulation of high-risk melanoma patients with unknown primary.Journal for immunotherapy of cancer · 2022Trial
- TCASIA: an integrative atlas linking alternative splicing landscapes for cancer immunotherapy.Journal for immunotherapy of cancer · 2026Article
- Comprehensive identification of FoxO signaling as a promising prognostic and immunotherapeutic biomarker in glioma.Journal of neuropathology and experimental neurology · 2026Article
- Immune-pressure redistribution in resistance to PD-1/PD-L1 blockade: mechanisms, biomarkers, and therapeutic design.Molecular cancer · 2026Review
- Review
- NGFR induces melanoma invasion and immunotherapy resistance through myosin light chain 2 modulation.The EMBO journal · 2026Article
- PathTIGR: A pathway topology-informed graph representation learning framework for immunotherapy response prediction.Science advances · 2026Article
- Loss of tumor-infiltrating lymphocytes and poor response to immunotherapy in IDH GOF mutant melanoma.JCI insight · 2026Article
- Targeting VEGF signaling and stromal remodeling enhances chemoimmunotherapy efficacy in esophageal cancer.Journal for immunotherapy of cancer · 2026Article
- A longitudinal, multi-omic atlas reveals the emergence of a spatially organized immunosuppressive ecosystem in resistant melanoma.Cell reports. Medicine · 2026Article
- Single-cell and spatial profiling in cancer biology and clinical oncology.Nature cancer · 2026Review
- Spatial proteomics in precision medicine: technologies, bioinformatics, and translational applications.Precision clinical medicine · 2026Review
- Single-cell advances in the investigation of the pathogenesis and treatment of brain metastasis.Neuro-oncology advances · 2026Review
- S-nitrosylation of IRF7 induced by NOS1 expression in melanoma suppresses anti-tumor immunity.Cell death & disease · 2026Article
- Exposure-response relationship of sintilimab in advanced gastric cancer: insights from time-dependent pharmacokinetics and biomarker integration for precision immunotherapy.Frontiers in pharmacology · 2026Review
- Overcoming impaired antigen presentation in tumor-draining lymph nodes facilitates immunotherapy.Journal for immunotherapy of cancer · 2025Article
- PathHDNN: a pathway hierarchical-informed deep neural network framework for predicting immunotherapy response and mechanism interpretation.Genome medicine · 2025Article
21 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
40 authors at 8 institutions in 1 country.
David Liu *Dana-Farber Cancer Institute, Boston, MA, USA.
Jia-Ren Lin *Laboratory of Systems Pharmacology, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0003-4702-7705
Emily J RobitschekDana-Farber Cancer Institute, Boston, MA, USA.
Gyulnara G KasumovaDivision of Surgical Oncology, Department of Surgery, Massachusetts General Hospital, Boston, MA, USA.
Alex HeydeProgram for Evolutionary Dynamics, Harvard University, Cambridge, MA, USA.
Alvin ShiBroad Institute of Harvard and MIT, Cambridge, MA, USA.
Adam KrayaDivision of Translational Medicine and Human Genetics, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Gao ZhangMolecular and Cellular Oncogenesis Program, The Wistar Institute, Philadelphia, PA, USA.
Tabea MollDivision of Medical Oncology, Department of Medicine, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
Dennie T FrederickDivision of Medical Oncology, Department of Medicine, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
Yu-An ChenLaboratory of Systems Pharmacology, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0001-7228-4696
Shu WangLaboratory of Systems Pharmacology, Harvard Medical School, Boston, MA, USA.
Denis SchapiroLaboratory of Systems Pharmacology, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0002-9391-5722
Li-Lun HoBroad Institute of Harvard and MIT, Cambridge, MA, USA.
Kevin BiDana-Farber Cancer Institute, Boston, MA, USA.
Avinash SahuDana-Farber Cancer Institute, Boston, MA, USA.
Shaolin MeiDana-Farber Cancer Institute, Boston, MA, USA.
Benchun MiaoDivision of Medical Oncology, Department of Medicine, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
Tatyana SharovaDivision of Surgical Oncology, Department of Surgery, Massachusetts General Hospital, Boston, MA, USA.
Christopher Alvarez-BreckenridgeDepartment of Neurosurgery, Harvard Medical School, Massachusetts General Hospital, Boston, MA, USA.
Jackson H StockingDivision of Medical Oncology, Department of Medicine, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0003-2759-2125
Tommy KimDivision of Surgical Oncology, Department of Surgery, Massachusetts General Hospital, Boston, MA, USA.
Riley FaddenDivision of Medical Oncology, Department of Medicine, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
Donald LawrenceDivision of Medical Oncology, Department of Medicine, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
Mai P HoangDepartment of Pathology, Harvard Medical School, Massachusetts General Hospital, Boston, MA, USA.ORCID http://orcid.org/0000-0002-1406-7981
Daniel P CahillDepartment of Neurosurgery, Harvard Medical School, Massachusetts General Hospital, Boston, MA, USA.
Mohsen MalehmirBroad Institute of Harvard and MIT, Cambridge, MA, USA.ORCID http://orcid.org/0000-0001-6915-5850
Martin A NowakProgram for Evolutionary Dynamics, Harvard University, Cambridge, MA, USA.ORCID http://orcid.org/0000-0001-5489-0908
Priscilla K BrastianosDivision of Medical Oncology, Department of Medicine, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0003-4470-8425
Christine G LianDepartment of Pathology, Harvard Medical School, Brigham and Woman's Hospital, Boston, MA, USA.
Eytan RuppinCancer Data Science Lab, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.ORCID http://orcid.org/0000-0002-7862-3940
Benjamin IzarDivision of Hematology and Oncology, Columbia University Irving Medical Center, New York, NY, USA.ORCID http://orcid.org/0000-0003-2379-6702
Meenhard HerlynMolecular and Cellular Oncogenesis Program, The Wistar Institute, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0003-0839-0739
Eliezer M Van AllenDana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0002-0201-4444
Katherine NathansonDivision of Translational Medicine and Human Genetics, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0002-6740-0901
Keith T FlahertyDivision of Medical Oncology, Department of Medicine, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
Ryan J SullivanDivision of Medical Oncology, Department of Medicine, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0001-5344-6645
Manolis KellisBroad Institute of Harvard and MIT, Cambridge, MA, USA.ORCID http://orcid.org/0000-0001-7113-9630
Peter K SorgerLaboratory of Systems Pharmacology, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0002-3364-1838
Genevieve M BolandBroad Institute of Harvard and MIT, Cambridge, MA, USA. gmboland@mgh.harvard.edu.ORCID http://orcid.org/0000-0002-7522-6173
Harvard University · USBroad Institute · USMassachusetts General Hospital · USThe Wistar Institute · USUniversity of Pennsylvania · USColumbia University Irving Medical Center · USDana-Farber Cancer Institute · USNational Institutes of Health · US
Funding
Tumor Microenvironment and MetastasisP30CA010815 · NCI · WISTAR INSTITUTE · PI Luis J Montaner · 1985 to 2026
$75.9MTargeting the MAP and PI3 Kinase Pathways in MelanomaP01CA114046 · NCI · WISTAR INSTITUTE · PI HERLYN, MEENHARD F, WEERARATNA, ASHANI T · 2008 to 2023
$37.1MResearch Project 2 - Targeting Melanoma Tumor Survival and Apoptotic MachineryU54CA224070 · NCI · WISTAR INSTITUTE · PI Michael Davies, Meenhard F Herlyn · 2017 to 2026
$13.9MTargeted Combination Therapy for MelanomaP50CA174523 · NCI · WISTAR INSTITUTE · PI HERLYN, MEENHARD F · 2014 to 2018
$11.1MSystems Pharmacology of Therapeutic and Adverse Responses to ImmuneCheckpoint and Small Molecule DrugsU54CA225088 · NCI · HARVARD MEDICAL SCHOOL · PI SORGER, PETER KARL · 2018 to 2022
$10.8MComputational studies of cancer immunotherapyZIABC011803 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI RUPPIN, EYTAN · 2018 to 2025
$10.7MGraduate Training in Computational and Systems BiologyT32GM087237 · NIGMS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI BURGE, CHRISTOPHER B · 2009 to 2023
$4.6MPostdoctoral Training Program in Genomic MedicineT32HG009495 · NHGRI · UNIVERSITY OF PENNSYLVANIA · PI Katherine L. Nathanson, Bogdan Pasaniuc · 2017 to 2026
$4.2MUsing MRI and circulating tumor DNA to improve the interpretation of response to immunotherapy and targeted therapy in CNS metastasesR01CA244975 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI BRASTIANOS, PRISCILLA KALIOPI, GERSTNER, ELIZABETH · 2020 to 2024
$3.4MIntegrative Somatic and Germline Computational Biology to Redefine Clinical Actionability in Solid TumorsR01CA227388 · NCI · DANA-FARBER CANCER INST · PI VAN ALLEN, ELIEZER M · 2018 to 2022
$2.0MDissecting Therapeutic Resistance and Progression in Metastatic Melanoma Through Clinical Computational OncologyK08CA234458 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI LIU, DAVID · 2018 to 2022
$1.2MDissecting mechanisms of immunotherapy resistance in melanoma patientsK08CA222663 · NCI · DANA-FARBER CANCER INST · PI IZAR, BENJAMIN · 2017 to 2021
$827kNCI NIH HHS K08 CA222663NCI NIH HHS K08 CA234458NCI NIH HHS L30 CA220913NCI NIH HHS P01 CA114046NCI NIH HHS P30 CA010815NCI NIH HHS P50 CA174523NCI NIH HHS R01 CA227388NCI NIH HHS R01 CA244975NCI NIH HHS U54 CA224070NCI NIH HHS U54 CA225088NHGRI NIH HHS T32 HG009495NIGMS NIH HHS T32 GM087237
Abstract
Despite initial responses
Indexed as
B7-H1 AntigenChromosomes, Human, Pair 15Drug Resistance, NeoplasmFemaleGene Expression Regulation, NeoplasticHumansImmune Checkpoint InhibitorsImmunotherapyMaleMelanomaNeoplasm MetastasisNeoplasm Recurrence, LocalNerve Tissue ProteinsPhylogenyReceptors, Nerve Growth FactorTumor MicroenvironmentB7-H1 AntigenImmune Checkpoint InhibitorsNerve Tissue ProteinsNGFR protein, humanReceptors, Nerve Growth Factor
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.